CN100537542C - 用作抗肿瘤剂的法呢基蛋白质转移酶抑制剂 - Google Patents

用作抗肿瘤剂的法呢基蛋白质转移酶抑制剂 Download PDF

Info

Publication number
CN100537542C
CN100537542C CNB038047209A CN03804720A CN100537542C CN 100537542 C CN100537542 C CN 100537542C CN B038047209 A CNB038047209 A CN B038047209A CN 03804720 A CN03804720 A CN 03804720A CN 100537542 C CN100537542 C CN 100537542C
Authority
CN
China
Prior art keywords
alkyl
compound
group
substituting group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038047209A
Other languages
English (en)
Chinese (zh)
Other versions
CN1630641A (zh
Inventor
H·Y·朱
F·G·恩乔洛吉
A·B·库珀
T·J·古兹
D·F·拉恩
K·P·米诺尔
R·J·多尔
V·M·吉利加法拉布汗
B·圣珊纳
P·A·平托
B·维布尔巴汉
K·M·基尔堤卡
C·S·阿尔瓦雷兹
J·J·包德温
李格
黄家育
R·A·詹姆士
W·R·比肖普
J·J·-S·王
J·A·德塞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia Drug Discovery Inc
Merck Sharp and Dohme LLC
Original Assignee
Pharmacopeia Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Pharmacopeia Inc, Schering Corp filed Critical Pharmacopeia Inc
Publication of CN1630641A publication Critical patent/CN1630641A/zh
Application granted granted Critical
Publication of CN100537542C publication Critical patent/CN100537542C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB038047209A 2002-02-27 2003-02-25 用作抗肿瘤剂的法呢基蛋白质转移酶抑制剂 Expired - Fee Related CN100537542C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/085,896 2002-02-27
US10/325,896 2002-12-19
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents

Publications (2)

Publication Number Publication Date
CN1630641A CN1630641A (zh) 2005-06-22
CN100537542C true CN100537542C (zh) 2009-09-09

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038047209A Expired - Fee Related CN100537542C (zh) 2002-02-27 2003-02-25 用作抗肿瘤剂的法呢基蛋白质转移酶抑制剂

Country Status (19)

Country Link
US (1) US7342016B2 (https=)
EP (1) EP1492772A1 (https=)
JP (1) JP2005525356A (https=)
KR (1) KR20040098004A (https=)
CN (1) CN100537542C (https=)
AR (1) AR039557A1 (https=)
AU (1) AU2003215389B2 (https=)
BR (1) BR0308071A (https=)
CA (1) CA2477328A1 (https=)
CO (1) CO5611194A2 (https=)
IL (1) IL163673A0 (https=)
MX (1) MXPA04008303A (https=)
NO (1) NO20044053L (https=)
NZ (1) NZ534809A (https=)
PE (1) PE20031038A1 (https=)
PL (1) PL372335A1 (https=)
RU (1) RU2004128465A (https=)
TW (1) TW200303867A (https=)
WO (1) WO2003072549A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
EP1660477B1 (en) * 2003-08-07 2008-12-10 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
KR20070034524A (ko) * 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
KR20070034049A (ko) 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
EP1833481A1 (en) 2004-12-14 2007-09-19 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CN101124219A (zh) * 2004-12-21 2008-02-13 先灵公司 用作抗肿瘤剂的新的法呢基蛋白质转移酶抑制剂
JP2009523799A (ja) * 2006-01-19 2009-06-25 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターとしてのピペラジン誘導体
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
HUE029445T2 (en) * 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
CA2730190A1 (en) 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
CN115385892A (zh) * 2021-10-28 2022-11-25 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010516A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1998054966A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. A method of treating cancer
CN1209127A (zh) * 1995-12-22 1999-02-24 先灵公司 三环酰胺类用于抑制g－蛋白功能及治疗增生疾病
WO2001045740A2 (en) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
WO2001056552A2 (en) * 2000-02-04 2001-08-09 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) * 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
US5416087A (en) * 1990-10-10 1995-05-16 Wong; Jesse K. Bis-benzo, cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
CN1237176A (zh) * 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
AU8253698A (en) 1997-06-17 1999-01-04 Schering Corporation Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
ZA985205B (en) 1997-06-17 1998-12-15 Schering Corp Novel n-substituted urea inhibitors of arnesyl-protein transferase
CN1266433A (zh) 1997-06-17 2000-09-13 先灵公司 用于抑制法呢基蛋白转移酶的苯并吡啶并环庚烷化合物
IL133449A0 (en) 1997-06-17 2001-04-30 Schering Corp Benzo (5, 6) cyclohepta (1, 2-b) pyridine derivatives as farnesyl protein transferase inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
EP1660477B1 (en) * 2003-08-07 2008-12-10 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010516A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CN1209127A (zh) * 1995-12-22 1999-02-24 先灵公司 三环酰胺类用于抑制g－蛋白功能及治疗增生疾病
WO1998054966A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. A method of treating cancer
WO2001045740A2 (en) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
WO2001056552A2 (en) * 2000-02-04 2001-08-09 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer

Also Published As

Publication number Publication date
EP1492772A1 (en) 2005-01-05
BR0308071A (pt) 2004-12-21
AU2003215389B2 (en) 2007-10-18
NO20044053L (no) 2004-11-26
KR20040098004A (ko) 2004-11-18
TW200303867A (en) 2003-09-16
JP2005525356A (ja) 2005-08-25
IL163673A0 (en) 2005-12-18
MXPA04008303A (es) 2005-11-23
RU2004128465A (ru) 2005-09-27
CA2477328A1 (en) 2003-09-04
NZ534809A (en) 2007-12-21
US7342016B2 (en) 2008-03-11
US20040122018A1 (en) 2004-06-24
AU2003215389A1 (en) 2003-09-09
WO2003072549A1 (en) 2003-09-04
PE20031038A1 (es) 2004-01-10
CO5611194A2 (es) 2006-02-28
CN1630641A (zh) 2005-06-22
AR039557A1 (es) 2005-02-23
PL372335A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
CN100537542C (zh) 用作抗肿瘤剂的法呢基蛋白质转移酶抑制剂
EP2132178B1 (en) Jnk inhibitors
EP2260031B1 (en) Compounds that are erk inhibitors
AU2007218059A1 (en) Pyrrolidine derivatives as ERK inhibitors
CN100384837C (zh) 作为抗肿瘤剂的法呢基蛋白质转移酶抑制剂
US20030229099A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
JP2005515201A (ja) 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用
EP1660477B1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
JP2005525356A5 (https=)
US20070213340A1 (en) Farnesyl protein transferase inhibitors
US7635697B2 (en) Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
TWI309649B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
HK1087122B (en) Novel farnesyl protein transferase inhibitors as antitumor agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Owner name: PHARMECPIA DRUG R & D CO., LTD.

Free format text: FORMER OWNER: PHARMACOPEIA INC.

Effective date: 20050624

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20050624

Address after: American New Jersey

Applicant after: SCHERING CORP (US)

Co-applicant after: Pharmacopeia Drug Discovery

Address before: American New Jersey

Applicant before: SCHERING CORP (US)

Co-applicant before: Pharmacopeia Inc.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090909

Termination date: 20120225